Vindesine
Tubulin Inhibitor
DB00309
Approved Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.
Details
DrugBank ID
DB00309 ↗
Approval Date
—
Molecular Weight
753.9261 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01CA03
Synonyms
Desacetylvinblastine amide
PubChem
CID: 40839 ↗
ChEMBL
CHEMBL219146 ↗
SMILES
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
ADMET Profile
Computing properties…